Using its drug delivery technology, MEDESIS PHARMA has implemented two drug programs
Medesis is a clinical development stage biopharmaceutical company that is engaged
AONYS® allows the administration of low doses of water-soluble pharmaceutical active
NP03 is a disease-modifying nano dose formulation of lithium citrate in an AONYS®
Preclinical studies on the disease-modifying effect of NP03 in AD have been conducted
After a civil or military nuclear accident, there are no suitable decorporation treatments
Directly linked to 137Cs are numerous diseases not only limited to the increased
